Connor, Clark & Lunn Investment Management (CC&L)’s Apellis Pharmaceuticals APLS Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.06M | Sell |
118,724
-13,171
| -10% | -$228K | 0.01% | 854 |
|
|
2025
Q1 | $2.88M | Buy |
131,895
+118,417
| +879% | +$2.59M | 0.01% | 634 |
|
|
2024
Q4 | $430K | Buy |
+13,478
| New | +$430K | ﹤0.01% | 1180 |
|
|
2023
Q3 | – | Sell |
-149,976
| Closed | -$13.7M | – | 1353 |
|
|
2023
Q2 | $13.7M | Sell |
149,976
-2,019
| -1% | -$184K | 0.07% | 208 |
|
|
2023
Q1 | $10M | Buy |
151,995
+75,114
| +98% | +$4.95M | 0.05% | 253 |
|
|
2022
Q4 | $3.98M | Buy |
76,881
+71,567
| +1,347% | +$3.7M | 0.02% | 394 |
|
|
2022
Q3 | $363K | Buy |
+5,314
| New | +$363K | ﹤0.01% | 879 |
|
|
2022
Q1 | – | Sell |
-9,406
| Closed | -$445K | – | 1028 |
|
|
2021
Q4 | $445K | Sell |
9,406
-68,089
| -88% | -$3.22M | ﹤0.01% | 822 |
|
|
2021
Q3 | $2.55M | Buy |
77,495
+59,074
| +321% | +$1.95M | 0.01% | 473 |
|
|
2021
Q2 | $1.16M | Buy |
+18,421
| New | +$1.16M | 0.01% | 647 |
|